Occuity choose Surface Technology International (STI) as manufacturing partner for PM1 Pachymeter

Updated: Oct 7

Occuity, a UK-based medical technology start-up, is delighted to announce that they have chosen a leading technology, engineering and electronics manufacturing specialists Surface Technology International (STI) to support with the manufacturing of their first ophthalmic product – The Occuity PM1 pachymeter.


STI will provide engineering services and will deliver manufacturing cell to support launch of the PM1 pachymeter.


After a competitive review and selection process STI was selected because of its extensive experience working as a specialist contract electronics manufacturer for a large number of world-class customers in high-reliability industries and its ISO 13485 accreditation which certifies that it has the robust quality management systems needed to provide medical devices and related services that consistently meet customer and applicable regulatory requirements.


Occuity have been provided with dedicated space within STI’s facilities and, working in collaboration, engineering teams from Occuity and STI have already started gearing up for the manufacture of the first batch of PM1 Pachymeters which will be used in upcoming clinical trials. This follows extensive collaboration over the previous months, utilizing STI’s electronics design, test development and design for manufacturing (DFM) services.


Founded in 1989, STI specialises in the Aerospace, Defence and Security sectors as well as Energy, Healthcare, Communications and Industrial – particularly higher volume Internet of Things (IoT) products. Headquartered in the UK, STI have state-of-the-art facilities in Hampshire, Cheshire and Cebu, Philippines.


Occuity CEO and Co-Founder Dan Daly commented:

Key partnerships are vital to the successful delivery of our products. As a UK-based company, conveniently located just a few miles from our own offices, partnering with STI has already realised significant benefits.

Head of Sales EMEA Jason Arnold from STI said: “We are thrilled to continue our ongoing partnerships with Occuity. We will bring further value to our collaboration to help this critical and disruptive product successfully enter the market and grow share.”


Due to launch in 2022, the Occuity PM1’s non-contacting design and patented optical technology will deliver a number of key advantages over existing treatment methods, ultimately improving the experience for customers and making it easier and more time and cost effective for practitioners.

57 views0 comments